Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
AIM: To assess synaptic density and to investigate the potential relationship of regional synaptic loss with motor and non-motor symptoms and with disease progression in the human brain in vivo in patients with PD.
DESIGN: We will include 30 PD patients and 20 healthy controls. All subjects will undergo a clinical examination, with comprehensive assessment of motor and non-motor symptoms, and imaging evaluation consisting of 11C-UCB-J PET-CT and 18F-FE-PE2I PET-MR at baseline and after 2 years.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PD patients | Experimental | At baseline and 2-year follow-up |
|
| Healthy controls | Active Comparator | At baseline and 2-year follow-up |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 11C-UCB-J PET-CT | Other | Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Baseline differences in synaptic density. | Baseline differences (%) in synaptic density between patients and controls. | Data analysis wel be done when all subjects have undergone the baseline evaluation. |
| Correlations between clinical scores and synaptic density. | Correlations between clinical scores and synaptic density in the patient group. | Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation. |
| Differences in the rate of decline of synaptic density. | Differences (%) in the rate of decline of synaptic density between patients and controls. | Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation. |
| Correlations between progression of the clinical scores and decline of synaptic density. | Correlations between progression of the clinical scores and decline of synaptic density in the patient group. | Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation. |
| Measure | Description | Time Frame |
|---|---|---|
| Baseline differences in DAT levels. | Baseline differences (%) in DAT levels between patients and controls. | Data analysis wel be done when all subjects have undergone the baseline evaluation. |
| Correlations between clinical scores and DAT levels. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Wim Vandenberghe, MD, PhD | UZ Leuven | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UZ Leuven | Leuven | Vlaams-Brabant | 3000 | Belgium |
Needs to be decided.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Longitudinal study design (2 years follow up) where results of SV2A PET/CT, PE2I PET/MR and clinical rating scales are compared between PD patients and healthy controls.
Not provided
Not provided
Not provided
Not provided
| 18F-PE2I PET-MR | Other | Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I, and brain MRI performed simultaneously. |
|
Correlations between clinical scores and DAT levels in the patient group.
| Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation. |
| Differences in the rate of decline of global and DAT levels. | Differences (%) in the rate of decline of global and DAT levels between patients and controls. | Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation. |
| Correlations between progression of the clinical scores and decline of DAT levels. | Correlations between progression of the clinical scores and decline of DAT levels in the patient group. | Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation. |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |